Voyager Therapeut (VYGR) Stock Price, Quote & News

Company Profile

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neu...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 259 5340

Website: www.voyagertherapeutics.com

Address:

75 Hayden Avenue, Lexington, United States

ASTANA Aug. 18 at 7:44 PM

$VYGR

0 · Reply

ASTANA Aug. 18 at 7:41 PM

$VYGR tracer

0 · Reply

tumanako Aug. 16 at 8:33 AM

$VYGR Bollinger Band sits well inside Keltner Channel, typical squeeze. Just wait for the squeeze to release, wheter to upside or downside. So far, no red bar appears. Keep finger crossed until the clinical trial results out.

0 · Reply

Estimize Aug. 12 at 8:03 PM

Wall St is expecting -0.42 EPS for $VYGR Q3 [Reporting 11/10 AMC] http://www.estimize.com/intro/vygr?chart=historical&metric_name=eps&utm_c

0 · Reply

Orlandotrader Aug. 7 at 10:45 PM

$VYGR Back in with 2,000 at 3$. Time to Shit or get off the Pot Voyager. Phase 1 Readout in Fourth Quarter. Most likely November. This company like some others go public way too early and live off the Donations of big pharma or thru Equity Raises. Other companies like this are Zura bio and FogHorn. Been around way too early before actual Clinical Trials. Usually the Results are all the same . Stocks trade near 52 week lows. Moral of the story is don’t let management have your money without a Clinical Trials in progress. We should hopefully move up in next Few Months in anticipation of Reading.

2 · Reply

0fabiocoppola Aug. 7 at 8:39 PM

$VYGR no conference call?

0 · Reply

JFDI Aug. 6 at 11:11 PM

$VYGR threw some alerts at 5 & 8 bucks

0 · Reply

pickens1 Aug. 6 at 9:11 PM

$VYGR Ended Q2 2026 with cash position of $149 million, runway into 2028 - Anticipated Upcoming Milestones Q4 2026: VY1706 expected to begin dosing in adults with early AD Q4 2026: VY7523 tau PET imaging data expected in MAD clinical trial in AD H2 2026: Neurocrine intends to initiate a clinical trial with NBIB-'223 for Friedreich's ataxia, pending successful FDA IND clearance Early 2027: Potential for initial acute safety data with VY1706, pending enrollment H2 2027: Potential for initial biomarker-based data for VY1706, pending enrollment

0 · Reply

focafoca99 Aug. 6 at 8:13 PM

$VYGR announced its Q2 2026 financial results and corporate updates.

0 · Reply

tumanako Jul. 28 at 12:32 AM

$VYGR ready to make the next major move, whether it be up or down. Technically, it points to down, but i hope otherwise.

0 · Reply

Voyager Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 14 days ago

Voyager Therapeutics Earnings release: Q2 2026

Jul 13, 2026, 8:01 AM EDT - 5 weeks ago

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026

Jun 29, 2026, 8:01 AM EDT - 7 weeks ago

Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

Jun 15, 2026, 7:00 AM EDT - 2 months ago

Voyager Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 12, 2026, 1:15 PM EDT - 2 months ago

UNLOCKING SPACE: Elon Musk is BREAKING RECORDS for orbital launches

SPCX

Jun 11, 2026, 4:01 PM EDT - 2 months ago

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

Jun 9, 2026, 9:00 AM EDT - 2 months ago

Voyager Therapeutics Transcript: AGM 2026

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease

May 13, 2026, 6:01 AM EDT - 3 months ago

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026

May 7, 2026, 4:01 PM EDT - 3 months ago

Voyager Reports First Quarter 2026 Financial and Operating Results

May 7, 2026, 7:00 AM EDT - 3 months ago

Voyager Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Voyager Therapeutics Earnings release: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Voyager Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Voyager Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 4:31 PM EDT - 4 months ago

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Voyager Therapeutics Proxy statement: Proxy filing

Mar 18, 2026, 12:30 PM EDT - 5 months ago

Voyager Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 9, 2026, 4:01 PM EDT - 5 months ago

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Voyager Therapeutics Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Voyager Therapeutics Annual report: Q4 2025

Feb 26, 2026, 3:20 PM EST - 6 months ago

Voyager Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 9, 2026, 8:00 AM EST - 6 months ago

Voyager to Present at Upcoming Investor Conferences

Nov 11, 2025, 3:20 PM EST - 10 months ago

Voyager Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 8:01 AM EST - 10 months ago

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia

Nov 10, 2025, 8:01 AM EST - 10 months ago

Voyager Reports Third Quarter 2025 Financial and Operating Results

Nov 10, 2025, 8:00 AM EST - 10 months ago

Voyager Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 8:00 AM EST - 10 months ago

Voyager Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Voyager Therapeutics Registration statement: Registration Filing

Sep 9, 2025, 9:05 AM EDT - 1 year ago

Voyager Therapeutics Transcript: Baird Global Healthcare Conference 2025

Sep 2, 2025, 4:00 PM EDT - 1 year ago

Voyager Therapeutics Transcript: Citi's Biopharma Back to School Conference

Aug 6, 2025, 4:01 PM EDT - 1 year ago

Voyager Reports Second Quarter 2025 Financial and Operating Results

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Voyager Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Voyager Therapeutics Earnings release: Q2 2025

Jul 16, 2025, 7:00 AM EDT - 1 year ago

Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Voyager Therapeutics Transcript: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 10, 2025, 7:00 AM EDT - 1 year ago

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

May 15, 2025, 7:00 AM EDT - 1 year ago

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

May 6, 2025, 4:01 PM EDT - 1 year ago

Voyager Reports First Quarter 2025 Financial and Operating Results

May 6, 2025, 4:00 PM EDT - 1 year ago

Voyager Therapeutics Quarterly report: Q1 2025

May 6, 2025, 4:00 PM EDT - 1 year ago

Voyager Therapeutics Earnings release: Q1 2025

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Voyager Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Voyager Therapeutics Proxy statement: Proxy Filing

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

Mar 19, 2025, 11:00 AM EDT - 1 year ago

Voyager Therapeutics Transcript: Virtual CNS Forum

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Voyager Therapeutics Earnings Call Transcript: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Voyager Therapeutics Annual report: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Voyager Therapeutics Earnings release: Q4 2024

Mar 11, 2025, 4:01 PM EDT - 1 year ago

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Mar 4, 2025, 7:00 AM EST - 1 year ago

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

Mar 3, 2025, 1:50 PM EST - 1 year ago

Voyager Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 7:00 AM EST - 1 year ago

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease

Feb 25, 2025, 7:00 AM EST - 1 year ago

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

Feb 11, 2025, 2:40 PM EST - 1 year ago

Voyager Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 7:00 AM EST - 1 year ago

Voyager Provides Update on SOD1 ALS Gene Therapy Program

Nov 18, 2024, 9:45 AM EST - 1 year ago

Voyager Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 2:00 PM EST - 1 year ago

Voyager Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 12, 2024, 4:30 PM EST - 1 year ago

Voyager Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Voyager Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Voyager Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:01 PM EST - 1 year ago

Voyager Reports Third Quarter 2024 Financial and Operating Results

Nov 5, 2024, 7:00 AM EST - 1 year ago

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

Sep 11, 2024, 1:25 PM EDT - 2 years ago

Voyager Therapeutics Transcript: Baird's 2024 Global Healthcare Conference

Sep 5, 2024, 1:30 PM EDT - 2 years ago

Voyager Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:01 PM EDT - 2 years ago

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 14, 2024, 9:30 AM EDT - 2 years ago

Voyager Therapeutics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 4:01 PM EDT - 2 years ago

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

Jun 27, 2024, 7:00 AM EDT - 2 years ago

Voyager Therapeutics Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 20, 2024, 1:35 PM EDT - 2 years ago

Voyager Therapeutics Transcript: TD Cowen Genetic Medicines & RNA Summit

Jun 13, 2024, 4:01 PM EDT - 2 years ago

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

Jun 13, 2024, 7:00 AM EDT - 2 years ago

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

May 16, 2024, 7:00 AM EDT - 2 years ago

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's Disease

May 13, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics Earnings Call Transcript: Q1 2024

May 13, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics Quarterly report: Q1 2024

May 13, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics Earnings release: Q1 2024

May 13, 2024, 4:01 PM EDT - 2 years ago

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

ASTANA Aug. 18 at 7:44 PM

$VYGR

0 · Reply

ASTANA Aug. 18 at 7:41 PM

$VYGR tracer

0 · Reply

tumanako Aug. 16 at 8:33 AM

0 · Reply

Estimize Aug. 12 at 8:03 PM

Wall St is expecting -0.42 EPS for $VYGR Q3 [Reporting 11/10 AMC] http://www.estimize.com/intro/vygr?chart=historical&metric_name=eps&utm_c

0 · Reply

Orlandotrader Aug. 7 at 10:45 PM

2 · Reply

0fabiocoppola Aug. 7 at 8:39 PM

$VYGR no conference call?

0 · Reply

JFDI Aug. 6 at 11:11 PM

$VYGR threw some alerts at 5 & 8 bucks

0 · Reply

pickens1 Aug. 6 at 9:11 PM

0 · Reply

focafoca99 Aug. 6 at 8:13 PM

$VYGR announced its Q2 2026 financial results and corporate updates.

0 · Reply

tumanako Jul. 28 at 12:32 AM

$VYGR ready to make the next major move, whether it be up or down. Technically, it points to down, but i hope otherwise.

0 · Reply

tumanako Jul. 26 at 2:13 PM

$VYGR BIIB80 trial provides the strongest evidence to date that tau reduction can be linked to clinical slowing, the degree of tau PET reduction did not track with the degree of clinical benefit in a straightforward dose-dependent way. The low-dose arm showed a CDR-SB treatment effect of 0.54 points — in the same range as (and slightly larger than) lecanemab’s 0.45, but not clearly “better than anti-amyloid antibodies (~0.5 point)” as a class.

0 · Reply

tumanako Jul. 26 at 3:28 AM

$VYGR https://endpoints.news/biogens-alzheimers-data-spur-excitement-confusion-about-tau-targeting-drugs/?u=50190b7a-f392-58f2-8035-66ba4105b2ea&s=email&c=79153abc-15dc3b12-81181e93

0 · Reply

somewon Jul. 23 at 2:51 PM

$VYGR this is trading essentially at cash value. Good phase 1/2 trial results later this year and this will either pop or be a cheap buyout for a big company

0 · Reply

buffalochips62 Jul. 22 at 2:14 PM

$VYGR whos NOT adding at these levels, and why not ?

0 · Reply

HarperLucky Jul. 21 at 10:30 PM

$VYGR Has a partnerships involving its capsid technology with major pharmaceutical companies, including programs connected to Novartis, Alexion/AstraZeneca Rare Disease and Neurocrine. These collaborations validate outside interest in its technology platform.

0 · Reply

StockScanners Jul. 18 at 8:32 AM

$VYGR keep watch if this holds above 3.10

0 · Reply

notreload_ai Jul. 14 at 2:57 PM

$BIIB diranersen showed robust tau reductions (50-65%) and slowed cognitive decline by up to 26% in its Phase 2 CELIA trial. Despite missing the primary endpoint, the drug advances to Phase 3 in 2027 with a favorable safety profile. Mixed Phase 2 results still advance the competitive tau gene-silencing space including $VYGR, $ARWR, and $DNLI. https://notreload.xyz/xy/biogen-diranersen-phase-2-results-promising-tau-drug-misses-primary-endpoint/

1 · Reply

LibertarianTreehugger Jul. 14 at 1:49 AM

Voyager's Alzheimer's Therapy Could Open a New Front in Treatment: https://jlsfund.substack.com/p/voyagers-alzheimers-therapy-could $VYGR

0 · Reply

tumanako Jul. 4 at 5:32 AM

$VYGR A Spread Triple Top is a classic Point and Figure (P&F) chart pattern defined by at least three resistance peaks separated by broader, non-adjacent retracements. A breakout occurs when the price punches through that ceiling, projecting a significant bullish move equal to the pattern's width multiplied by the box size

2 · Reply

tumanako Jul. 2 at 1:40 AM

$VYGR Shall have good news soon. It is a sleeper now.

0 · Reply

focafoca99 Jun. 29 at 12:13 PM

$VYGR presenting its tau-targeted gene therapy VY1706 at AAIC 2026 poster session.

0 · Reply

Reacting_ Jun. 14 at 10:10 AM

$VYGR

0 · Reply

Market Cap	203.34M
Revenue (ttm)	40.37M
Net Income (ttm)	-119.72M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-296.56%
Debt to Equity Ratio	0.00

Volume	716,919
Avg Vol	631,896
Day's Range	N/A - N/A
Shares Out	61.62M
Stochastic %K	83%
Beta	1.31
Analysts	Strong Sell
Price Target	$15.38